Pharmaceutical Executive
Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs.
Pharmaceutical Executive-02-05-2009
Advertisement
Advertisement
Trending on PharmExec
1
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
2
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
3
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
4
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
5